Stifel says Avidity trial update is 'positive' for muscle wasting treatments

Dyne Therapeutics

04/03/2024 13:57

** Brokerage Stifel says that trial results from Avidity
Biosciences'  RNA.O  muscle wasting treatment is a positive
update for other such treatments 
    ** Says RNA's decision to use video hand opening time (vHOT)
as the main goal for its late-stage trial is bullish for both
RNA and Dyne Therapeutics  DYN.O  as both companies have shown a
promising efficacy signal here
    ** In a vHOT test, patients with myotonic dystrophy type 1
(DM1) are asked to perform maximal handgrip for 5 seconds
followed by rapid extension of fingers, the speed of which is
video recorded and evaluated
    ** Brokerage says PepGen's  PEPG.O  DM1 study bears
watching, adding DM1 is a huge market so there is room for
multiple winners
    ** Up to last close, DYNE up more than double, PEPG up 7.4%
and RNA down 15.3% in the last 12 months

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))